세계의 바이오의약품 산업에 대해 조사했으며, 기업이 진단약 유통 계약에 참여하는 방법과 이유의 분석 및 2016-2025년의 진단 약 유통 계약에 관한 상세한 데이터를 제공하고 있습니다.
목차
개요
제1장 서론
제2장 유통 계약의 동향
서론
유통 계약의 정의
유통 계약의 동향(2016년-)
유통 계약 성립 : 연별(2016-2025년)
유통 계약 성립 : 개발 단계별(2016-2025년)
유통 계약 성립 : 치료 영역별(2016-2025년)
유통 계약 성립 : 기술 유형별(2016-2025년)
가장 활발한 기업에 의한 유통 계약 성립(2016-2025년)
유통 파트너 계약에 참여하는 이유
제3장 유통 계약 구조의 개요
서론
유통 계약 구조
제4장 주요 유통 계약
서론
금액별 상위 유통 계약
제5장 가장 활발한 유통 계약 기업 상위 25사
서론
가장 활발한 유통 계약 기업 상위 25사
계약 디렉토리
계약 디렉토리 - 유통 계약 성립 : 기업별(A-Z)
계약 디렉토리 - 유통 계약 성립 : 치료 영역별
계약 디렉토리 - 유통 계약 성립 : 기술 유형별
Biopharma Research 소개
Current Partnering
Current Agreements
Current Partnering으로부터의 최근 리포트 타이틀
KSA
영문 목차
영문목차
Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution deals.
Fully revised and updated, the report provides details of distribution deals from 2016 to 2025.
The report provides access to distribution deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of distribution deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual distribution contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of distribution dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in distribution as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of distribution deals.
Chapter 4 provides a review of the leading distribution deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active distribution dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
The deal directory includes a comprehensive listing of all distribution deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about distribution alliances.
Key benefits
Distribution Deals in Diagnostics provides the reader with the following key benefits:
Understand deal trends since 2016
Browse distribution deals
Benchmark analysis - identify market value of transactions
Financials terms
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Report scope
Distribution Deals in Diagnostics is intended to provide the reader with an in-depth understanding of the distribution trends and structure of deals entered into by leading biopharma companies worldwide.
Distribution Deals in Diagnostics includes:
Trends in distribution dealmaking in the biopharma industry
Overview of distribution deal structure
Directory of distribution deal records covering diagnostics
The leading distribution deals by value
Most active distribution dealmakers
The leading distribution partnering resources
In Distribution Deals in Diagnostics, the available deals are listed by:
Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Distribution Deals in Diagnostics provides comprehensive access to available records for distribution deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
What are the rights granted or optioned?
What rights are granted by the agreement?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are intellectual property rights handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in distribution dealmaking
2.1. Introduction
2.2. Definition of distribution deal
2.3. Trends in distribution deals since 2016
2.3.1. Distribution dealmaking by year, 2016-2025
2.3.2. Distribution dealmaking by phase of development, 2016-2025
2.3.3. Distribution dealmaking by therapy area, 2016-2025
2.3.4. Distribution dealmaking by technology type, 2016-2025
2.3.5. Distribution dealmaking by most active company, 2016-2025
2.4. Reasons for entering into distribution partnering deals
Chapter 3 - Overview of distribution deal structure
3.1. Introduction
3.2. Distribution agreement structure
Chapter 4 - Leading distribution deals
4.1. Introduction
4.2. Top distribution deals by value
Chapter 5 - Top 25 most active distribution dealmakers
5.1. Introduction
5.2. Top 25 most active distribution dealmakers
Deal directory
Deal directory - distribution dealmaking by companies A-Z
Deal directory - distribution dealmaking by therapy area
Deal directory - distribution dealmaking by technology type
About Biopharma Research
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Definition of distribution
Figure 2: Trends in distribution deal announcements, 2016 to 2025
Figure 3: Distribution deals signed at each phase of development, 2016 to 2025
Figure 4: Distribution deals by therapy area, 2016 to 2025
Figure 5: Distribution deals by technology type, 2016 to 2025
Figure 6: Top 25 most active distribution dealmakers, 2016 to 2025
Figure 7: Issues in implementing distribution agreements
Figure 8: Distribution agreements - what should a contract include?
Figure 9: Components of the distribution deal structure
Figure 10: Top distribution deals by value 2016 to 2025
Figure 11: Most active distribution dealmakers 2016 to 2025
